11th IAS Conference on HIV Science

IAS 2021 – the 11th IAS Conference on HIV Science – is the world’s most influential conference on HIV Science and will be held virtually on 18-21 July 2021.

The biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. IAS 2021 will include a “local partner hub” to convene locally based experts in the original host city of Berlin, in accordance with local health advice and regulations.

The HIV/AIDS Clinical Trials Networks will present research in oral sessions and e-poster formats.

Oral Presentations

Session times are listed in Central European Summer Time (CEST).

Date/Time Protocol Title Presenter
July 20, 12:00 - 12:50 CEST MTN-034 High adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa Gonasagrie Nair
July 21, 12:00 - 12:50 CEST HPTN 083-02 Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW Christina Psaros
On-Demand HPTN 084 Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP Mia Moore
On-Demand MTN-003 HPV increases HIV Risk in African Women: Advancing the argument or HPV immunization Gui Liu


All e-Posters are available on-demand.

Protocol Title Presenter
HPTN 061 Comparisons of associations between incarceration and sexual risk behavior and STI/HIV among Black sexual minority men in Six U.S. cities (HPTN 061) Jonathan Feelemyer
HPTN 068 Partnership dynamics and dual method use among adolescent girls and young women in South Africa: a longitudinal analysis of HIV Prevention Trials Network 068 data Nivedita L. Bhushan
HPTN 082 Trust in the PrEP provider is associated with accurate self-reported PrEP adherence among adolescent girls and young women in sub-Saharan Africa Geetha Beauchamp
HPTN 084 Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 Sinead Delany-Moretiwe
HVTN 704 / HPTN 085 HIV-1 Env markers of prevention efficacy in HVTN 704/HPTN 085, the Antibody-Mediated Prevention (AMP) trial of broadly neutralizing antibody (bnAb) VRC01 in the Americas and Europe: genotypic sieve analysis Craig Magaret
IMPAACT 2019 Pharmacokinetics and Safety of Dispersible and Immediate Release FDC Abacavir/ Dolutegravir/ Lamivudine in Children with HIV Weighing ≥14 kg: Preliminary Results from IMPAACT 2019 Kristina Brooks
IMPAACT PROMISE 1077BF  Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in HIV-1-Infected Postpartum Women in Promoting Maternal and Infant Survival Everywhere (PROMISE): Randomized, Open Label Trial in Sub-Saharan Africa and India Neetal Nevrekar
IMPAACT P1078 Prevalence of Depression among Postpartum Women on Isoniazid-Preventive Therapy and Efavirenz-based Treatment for HIV—An Exploratory Objective of the IMPAACT P1078 Randomized Trial Kristin Baltrusaitis
MTN-020 Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Exchange Sex Erica Browne
MTN-042 Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open-label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancy Katie Bunge
MTN-045 Making the case for joint decision-making: the influence of partner preferences on future dual prevention product use Miriam Hartmann
MTN-045 Couples' preferences for a dual-purpose product to prevent both HIV and pregnancy: results of a discrete choice experiment (DCE) in Uganda and Zimbabwe Alexandra Minnis